Identifying HTA Outcomes and Assessing Reimbursement Implications for Drug X Through Evidence-based Considerations

[vc_row][/vc_row][vc_row][vc_column width=”2/3″][vc_column_text]

Objective

The client’s objective was to understand HTA outcomes and reimbursement implications for a drug in Phase I for KRAS+ NSCLC patients in a particular region to support its SoC potential.[/vc_column_text][vc_column_text css=”.vc_custom_1726501568361{padding-top: 30px !important;}”]

Challenges faced by the client

The client faced significant challenges in determining whether Drug X, in Phase I for KRAS+ NSCLC patients, could be positioned as a standard of care (SoC) in third-line treatment. This was crucial for evidence generation, understanding reimbursement implications, and preparing a compelling value story for an upcoming Haute Autorité de Santé (HAS) meeting. The client needed clear guidance on SoC potential and the necessary evidence to secure favorable outcomes.[/vc_column_text][vc_column_text css=”.vc_custom_1726501599608{padding-top: 30px !important;}”]Want to know how we supported our client in comprehending the HTA outcomes and reimbursement implications of the drug in Phase I for KRAS+ NSCLC patients, particularly in France?[/vc_column_text][vc_column_text css=”.vc_custom_1726501629375{padding-top: 30px !important;}”]Fill out the form to access the full case study.[/vc_column_text][/vc_column][vc_column width=”1/3″]

Error: Contact form not found.